The Switzerland market recently experienced a downturn, influenced by geopolitical tensions and weak euro area economic data, with the benchmark SMI closing down by 0.91% amidst easing consumer price inflation to its lowest in over three years. In such a fluctuating environment, identifying high growth tech stocks requires careful consideration of their resilience and potential to adapt amid broader market uncertainties.
Top 10 High Growth Tech Companies In Switzerland
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| LEM Holding | 8.69% | 18.43% | ★★★★☆☆ |
| Santhera Pharmaceuticals Holding | 24.55% | 35.40% | ★★★★★★ |
| ALSO Holding | 12.69% | 24.49% | ★★★★☆☆ |
| Temenos | 7.60% | 14.36% | ★★★★☆☆ |
| SoftwareONE Holding | 8.59% | 52.33% | ★★★★★☆ |
| Comet Holding | 19.66% | 47.84% | ★★★★★☆ |
| Cicor Technologies | 7.10% | 27.73% | ★★★★☆☆ |
| Addex Therapeutics | 26.51% | 33.31% | ★★★★★☆ |
| Basilea Pharmaceutica | 9.24% | 34.42% | ★★★★★☆ |
| Sensirion Holding | 13.86% | 102.68% | ★★★★☆☆ |
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Basilea Pharmaceutica AG is a commercial-stage biopharmaceutical company specializing in developing products for oncology and anti-infectives, with a market cap of CHF544.84 million.
Operations: Basilea Pharmaceutica generates revenue primarily from the discovery, development, and commercialization of innovative pharmaceutical products, amounting to CHF149.02 million. The company’s focus on oncology and anti-infectives drives its business operations.
Basilea Pharmaceutica, navigating through a challenging biotech landscape, recently raised its 2024 revenue forecast to CHF 203 million and net profit expectations to CHF 60 million, signaling robust financial health. This upward revision follows significant regulatory advancements, including the extended market exclusivity for Cresemba® in the EU until October 2027, enhancing its competitive edge in antifungal treatments. Despite a dip in half-year revenues to CHF 76.29 million from CHF 84.91 million year-over-year and a decrease in net income to CHF 20.74 million from CHF 31.84 million, Basilea’s strategic R&D focus remains evident with an anticipated annual earnings growth of 34.4%. This commitment is set against a backdrop where its projected revenue growth of 9.2% annually outpaces the Swiss market’s average of 4.4%, positioning it favorably for future profitability within three years amidst high industry volatility.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Sensirion Holding AG is a company that develops, produces, sells, and services sensor systems, modules, and components globally with a market cap of CHF1.12 billion.
Operations: Sensirion Holding AG focuses on the development and sale of sensor systems, modules, and components, generating revenue of CHF237.91 million.
Sensirion Holding AG, amidst a challenging financial landscape with a recent net loss of CHF 36.01 million, contrasts sharply with its previous year’s net income of CHF 1.43 million. However, the company’s commitment to innovation is underscored by its R&D expenses which are notably high, reflecting its strategy to pivot and sustain long-term growth in the tech sector. This approach seems poised to foster recovery, as evidenced by an anticipated explosive annual earnings growth of 102.7%. Moreover, Sensirion’s revenue trajectory remains positive with a forecasted increase of 13.9% per year—outpacing the broader Swiss market’s average growth rate substantially. These figures illustrate a firm that, while currently facing profitability challenges, is investing heavily in future capabilities likely centered around its core sensor technologies and related markets.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Temenos AG develops, markets, and sells integrated banking software systems to financial institutions globally with a market cap of CHF4.30 billion.
Operations: The company generates revenue primarily from two segments: Product, contributing $879.99 million, and Services, adding $132.98 million.
Temenos, a Swiss software firm, is navigating the high-growth tech landscape with strategic executive hires and a robust share buyback program. In recent developments, the company repurchased 3.26 million shares for CHF 200 million, reflecting confidence in its financial health and commitment to shareholder value. Notably, Temenos’s R&D spending has been pivotal, maintaining an upward trajectory with a significant allocation of resources (14.4% of revenue), underscoring its focus on innovation in banking software solutions. This investment is complemented by a revenue growth forecast of 7.6% annually, outpacing the broader market’s 4.4%, positioning Temenos to capitalize on emerging opportunities in digital finance while enhancing its SaaS offerings and global market presence through strategic leadership appointments aimed at expanding its U.S operations.
Make It Happen
Ready To Venture Into Other Investment Styles?
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com